Seer, Inc. Stock Price, News & Analysis

Seer, Inc. (Nasdaq: SEER), a life sciences company specializing in proteomics, will release its financial results for Q1 2023 after market close on May 9, 2023. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, accessible via the Investor section of their website. Seer’s Proteograph™ Product Suite offers a breakthrough solution for unbiased proteomic analysis, streamlining laboratory workflows with engineered nanoparticles, consumables, automation, and software. Designed for research applications only, the Proteograph enables deep analysis in hours, enhancing lab efficiency.

Seer Inc. (NASDAQ: SEER) announced a study in PLOS One revealing new protein variants associated with non-small cell lung cancer (NSCLC) using the Proteograph Product Suite. Collaborating with Memorial Sloan Kettering Cancer Center, researchers identified four protein isoforms linked to NSCLC progression, highlighting their potential as new biomarkers. Notably, the short protein isoform of BMP1 was found more frequently in late-stage NSCLC patients. The analysis included 188 plasma samples from NSCLC patients and controls. Results underscore the importance of unbiased proteomics for advancing cancer research and diagnosis.

Seer Inc. (Nasdaq: SEER) reported a significant revenue increase of 134% in 2022, reaching $15.5 million, with fourth-quarter revenue of $4.6 million, a 50% year-over-year rise. Instruments shipped rose 129% with a total of 39 units by year-end. Despite growth, the company faced a net loss of $93.0 million for the year. Operating expenses surged to $104.3 million

, leading to a gross profit margin of 46%. For 2023, Seer forecasts revenue between $23 million and $25 million, indicating a growth rate of 48% to 61%.

Seer, a life sciences company specializing in proteomics, announced participation in the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 8, 2023. The company’s management will engage in a fireside chat and Q&A session at 9:50 a.m. Eastern Time. Investors can access the live webcast via Seer's website, with an archived replay available post-conference. Seer’s innovative Proteograph Product Suite facilitates deep proteomic analysis efficiently and is designed for laboratory use. This suite is not intended for diagnostic procedures and aims to enhance research capabilities in proteomics.

Seer, Inc. (Nasdaq: SEER) will report its financial results for Q4 and full year 2022 on March 2, 2023, after market close. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET, available via webcast on the Investor section of Seer’s website. Seer specializes in proteomics, offering the Proteograph Product Suite, which enables deep, unbiased proteomic analysis efficiently. This solution uses proprietary engineered nanoparticles and is designed for use in a variety of laboratory settings.

Seer, Inc. (Nasdaq: SEER) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. Management will present at 3:00 p.m. PT / 6:00 p.m. ET, followed by a Q&A session. Investors can access a live webcast on the Investor section of Seer's website, with an archived replay available afterwards.

Seer specializes in proteomics, offering the Proteograph™ Product Suite, a unique solution for deep proteomic analysis. For further details, visit www.seer.bio.

Discovery Life Sciences has launched a new Proteomic Services Division, accepting samples from various research entities to enhance drug and diagnostic development. This division integrates cutting-edge technologies, including the Seer Proteograph Product Suite and SCIEX LC-MS/MS systems. Discovery has formed a Proteogenomics Consortium with Seer and SCIEX to advance plasma proteomic studies, aimed at uncovering novel biomarkers. The company also highlighted its status as the largest certified provider for Olink's Proximity Extension Assay platform in the Americas.